newsfilter
← Latest News
GlobeNewswire·

Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update

APMD
  • The U.S. FDA accepted Apnimed's New Drug Application for AD109 (proposed name Oxnimbi) with a PDUFA target action date of February 28, 2027.
  • If approved, Oxnimbi aims to be the first oral pharmacologic therapy targeting the neuromuscular root cause of upper airway collapse in obstructive sleep apnea (OSA).
  • Apnimed completed an upsized initial public offering generating $220.8 million in gross proceeds, with common stock beginning Nasdaq trading under the ticker "APMD" on July 31, 2026.
  • The company strengthened its leadership team with appointments of Kevin Lind as CEO, Michael Kelly as CFO, and Steven Spector as Chief Legal Officer.
  • Apnimed monetized its interest in Shionogi-Apnimed Sleep Science for $100 million in upfront proceeds while securing a senior secured credit facility of up to $150 million.
  • Second quarter 2026 financial results showed net income of $125.9 million, driven by a $57.1 million gain on deposit liability reversal and an $85.4 million gain on the sale of an equity method investment.
  • Research and development expenses decreased to $9.9 million in Q2 2026 compared to $16.0 million in the prior year period due to the completion of Phase 3 trials.
  • General and administrative expenses increased to $12.7 million in Q2 2026, primarily due to infrastructure costs for commercial readiness and increased headcount.
  • Apnimed reported cash and cash equivalents of approximately $172.8 million as of June 30, 2026.
  • The company presented pooled Phase 3 trial data at ATS 2026 and SLEEP 2026 and published two peer-reviewed articles on Oxnimbi.
  • Apnimed's stock was included in a preliminary list for additions to the Russell 2000® Index effective September 21, 2026.
  • Upcoming investor events include a fireside chat at the Cantor Global Healthcare Conference 2026 on September 10, 2026.